Drug (ID: DG00324) and It's Reported Resistant Information
Name
Bendamustine hydrochloride
Synonyms
Treanda (TN)
    Click to Show/Hide
Indication
In total 1 Indication(s)
Leukaemia [ICD-11: 2A60-2B33]
Approved
[1]
Structure
Drug Resistance Disease(s)
Disease(s) with Clinically Reported Resistance for This Drug (2 diseases)
Chronic lymphocytic leukemia [ICD-11: 2A82]
[1]
Mature B-cell neoplasms/lymphoma [ICD-11: 2A85]
[2]
Target Human Deoxyribonucleic acid (hDNA) NOUNIPROTAC [1]
Click to Show/Hide the Molecular Information and External Link(s) of This Drug
Formula
C16H21Cl2N3O2
IsoSMILES
CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O
InChI
1S/C16H21Cl2N3O2/c1-20-14-6-5-12(21(9-7-17)10-8-18)11-13(14)19-15(20)3-2-4-16(22)23/h5-6,11H,2-4,7-10H2,1H3,(H,22,23)
InChIKey
YTKUWDBFDASYHO-UHFFFAOYSA-N
PubChem CID
65628
TTD Drug ID
D01CYA
INTEDE ID
DR0188
DrugBank ID
DB06769
Type(s) of Resistant Mechanism of This Drug
  UAPP: Unusual Activation of Pro-survival Pathway
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
Click to Show/Hide the Resistance Disease of This Class
Chronic lymphocytic leukemia [ICD-11: 2A82]
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Unusual Activation of Pro-survival Pathway (UAPP) Click to Show/Hide
Key Molecule: Cellular tumor antigen p53 (TP53) [1]
Molecule Alteration Mutation
.
Resistant Disease Chronic lymphocytic leukemia [ICD-11: 2A82.0]
Experimental Note Identified from the Human Clinical Data
In Vivo Model A retrospective survey in conducting clinical studies Homo sapiens
Experiment for
Molecule Alteration
Whole exome sequencing assay; Targeted deep sequencing assay; Sanger sequencing assay
Mechanism Description Following exposure to chemoimmunotherapy, the resistant TP53 aberrant clones accumulate and dominate the tumour.
Mature B-cell neoplasms/lymphoma [ICD-11: 2A85]
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Unusual Activation of Pro-survival Pathway (UAPP) Click to Show/Hide
Key Molecule: CXC chemokine receptor type 4 (CXCR4) [2]
Molecule Alteration Mutation
.
Resistant Disease Waldenstrom macroglobulinemia [ICD-11: 2A85.4]
Experimental Note Identified from the Human Clinical Data
Mechanism Description CXCR4 mutation led to bendamustine in the waldenstrom macroglobulinemia.
References
Ref 1 Longitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive disease. Leukemia. 2016 Jun;30(6):1301-10. doi: 10.1038/leu.2016.10. Epub 2016 Feb 5.
Ref 2 Genomics, Signaling, and Treatment of Waldenstr m Macroglobulinemia .J Clin Oncol. 2017 Mar 20;35(9):994-1001. doi: 10.1200/JCO.2016.71.0814. Epub 2017 Feb 13. 10.1200/JCO.2016.71.0814

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.